5 recruiting, 3 active not recruiting, 3 terminated, 2 completed. 9 Phase 2, 5 Phase 1, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Terminated 3, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Terminated 1 |
| Not applicable | 3 | Completed 2, Active not recruiting 1 |
Follow Stage IIIB Hepatocellular Carcinoma AJCC v8: new trials by email Literature Review of Stage IIIB Hepatocellular Carcinoma AJCC v8 trials Research Report on Stage IIIB Hepatocellular Carcinoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Y-90 Versus SBRT for Inoperable HCC Quality of Life, Questionnaire Administration, Stereotactic Body Radiation Therapy - Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8 | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2023-12-01 | 2023-03-23 | |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Ipilimumab, Nivolumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 15 | 2023-01-19 | 2026-08-04 |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Atezolizumab, Cabozantinib, Lenvatinib - Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 122 | 2022-05-27 | 2026-08-04 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant Laboratory Biomarker Analysis, Lenvatinib - Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Terminated | Emory University | 3 | 2022-04-19 | 2026-04-24 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma Durvalumab, Hypofractionated Radiation Therapy, Tremelimumab - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Recruiting | Mary Feng, MD | 21 | 2022-02-04 | 2025-12-08 |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Durvalumab, Tremelimumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 25 | 2021-08-03 | 2026-04-20 |
| Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2021-01-13 | 2026-09-14 |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Carboplatin, Paclitaxel, Pevonedistat - Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2020-03-16 | 2026-10-22 |
| Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) Computed Tomography, Hepatobiliary Iminodiacetic Acid Scan, Single Photon Emission Computed Tomography - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 42 | 2019-10-10 | 2026-05-22 |
| An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer Magnetic Resonance Elastography, Magnetic Resonance Imaging - Advanced Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Not applicable | Completed | M.D. Anderson Cancer Center | 6 | 2019-06-11 | 2025-02-19 |
| BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer IDO1 Inhibitor BMS-986205, Nivolumab - Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 1 / Phase 2 | Terminated | Edward Kim | 8 | 2018-10-16 | 2026-07-29 |
| Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma Yttrium Y 90 Glass Microspheres - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Not applicable | Completed | M.D. Anderson Cancer Center | 299 | 2010-08-04 | 2022-10-14 |
Carcinoma, Hepatocellular (14) · Carcinoma, Renal Cell (2) · Endometrial Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Cholangiocarcinoma (1) · Fallopian Tube Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Adenocarcinoma (14) · Carcinoma (14) · Digestive System Diseases (14) · Digestive System Neoplasms (14) · Liver Diseases (14) · Liver Neoplasms (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms by Site (14) · Neoplasms, Glandular and Epithelial (14) · Breast Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2)
Immunoglobulin G (3) · Nivolumab (3) · Disulfides (2) · Magnetic Resonance Spectroscopy (2) · Taxes (2) · X-Rays (2) · atezolizumab (2) · cabozantinib (2) · durvalumab (2) · lenvatinib (2) · tremelimumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Biopsy (1) · CTLA-4 Antigen (1)
M.D. Anderson Cancer Center (5) · Academic and Community Cancer Research United (2) · City of Hope Medical Center (1) · Edward Kim (1) · Emory University (1) · Mary Feng, MD (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1)
United States (13)
Armeen Mahvash (2) · Apostolia M Tsimberidou (1) · Daneng Li (1) · Dustin A Deming (1) · Edward Kim, MD, PhD (1) · Mary Feng, MD (1) · Mehmet Akce (1) · Nima Nabavizadeh (1) · Olumide B. Gbolahan, M.D. (1) · Priya Bhosale (1) · Sunyoung Lee (1) · Wen Wee Ma (1) · Yanyan Lou, MD, PhD (1)
P30CA015083 (2), P30CA016672 (2), P30CA033572 (1), P30CA093373 (1), P30CA138292 (1), U10CA180820 (1)